1 – 12 of 12
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant : Breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium
(
- Contribution to journal › Article
- 2017
-
Mark
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression : identification of a modifier of breast cancer risk at locus 11q22.3
(
- Contribution to journal › Article
- 2016
-
Mark
Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.
2016) In Nature Genetics(
- Contribution to journal › Article
-
Mark
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
(
- Contribution to journal › Article
-
Mark
Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus
(
- Contribution to journal › Article
- 2015
-
Mark
Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers.
(
- Contribution to journal › Article
-
Mark
Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants
(
- Contribution to journal › Article
- 2013
-
Mark
Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1
(
- Contribution to journal › Article
- 2012
-
Mark
BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk
(
- Contribution to journal › Article
-
Mark
Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk
(
- Contribution to journal › Article
- 2011
-
Mark
Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers
(
- Contribution to journal › Article
- 2010
-
Mark
Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers
(
- Contribution to journal › Article